Agreement provides Vector access to FDA-registered, cGMP facility and supports development of 24 novel shelf-stable peptide formulations targeting the $80.8 billion peptide market MEQUON, Wis., May 11 ...
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2026) - Vector Science and Therapeutics Corp. (TSXV: PAIN) (formerly OpenSesame Acquisition Corp.) ("Vector" or the "Company") is pleased to ...
Former Wisconsin Governor and U.S. Secretary of Health and Human Services Brings Extensive Healthcare Leadership to Pioneer of Transdermal Drug Delivery Technology MEQUON, Wis., April 30, 2026 ...
11d
Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform
Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the appointment of Dexter Fowler as Chief Athletic Officer ...
Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations MEQUON, Wis., May 13, 2026 /PRNewswire/ -- Vector Science & Therapeutics ...
The Company's stock option plan is a 10% rolling plan. As of the date hereof, a total of 6,556,610 common shares of the Company are reserved for issuance under the Company's stock option plan, with ...
Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations FDA-Registered, cGMP Manufacturing-- MPP operates a modern 35,000 sq. ft.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results